While large-scale clinical trials are required to evaluate the efficacy of dupilumab in pediatric prurigo nodularis, our case demonstrates that its role is promising and might be an important tool in prurigo nodularis when standard therapy failed. The optimal duration of treatment is still unknown because, as seen in other conditions treated with dupilumab,[6] some patients may experience disease recurrence after treatment suspension. Prurigo nodularis, first described by Hyde in 1909, is a rare (estimated incidence of 72 per 100,000 people) chronic skin disorder characterized by multiple firms, symmetrically distributed, excoriated, erythematous-to-brown nodules with intense pruritus. [Extracted from the article]